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ABSTRACT
Aim To estimate current clinical practice for frequency
of visual ﬁeld (VF) monitoring in glaucoma in England.
Methods A cross-sectional review of all patients with
chronic open angle glaucoma (COAG) attending
specialist glaucoma clinics at six hospitals in England
was performed. The number of VF tests undertaken prior
to the study date and during the ﬁrst 2 years since
diagnosis were recorded and compared with European
Glaucoma Society (EGS) guidelines for newly-diagnosed
patients. Clinician-requested monitoring intervals were
compared with intervals from the National Institute of
Clinical Excellence (NICE) guidelines, and the
relationships with disease severity, intraocular pressure
(IOP) and glaucoma progression status were reviewed.
Results One-hundred and four patients with COAG
were included. 73 patients had at least 2 years of
follow-up. Median (IQR) total number of VF tests and in
the ﬁrst 2 years of diagnosis were 4 (2–7) and 2 (2–3),
respectively. No patients met EGS guidelines, but 87%
of patients had their monitoring intervals requested in
accordance with NICE guidelines. These intervals were
not related to disease severity or VF stability (Kruskal–
Wallis test, p=0.25) but shortened signiﬁcantly when
IOP control was inadequate or when the overall clinical
impression was disease progression (p<0.001).
Conclusions Most newly-diagnosed COAG patients
receive less than three VFs in the ﬁrst 2 years following
diagnosis and an average of 0.7 VF per year over the
duration of follow-up.
INTRODUCTION
Patients with chronic open angle glaucoma
(COAG) represent a major workload of hospital
eye services.1 2 The guidelines for glaucoma pub-
lished by the National Institute of Clinical
Excellence (NICE) in the UK highlighted the lack
of evidence about how patients with the condition
should be monitored over time.3 The NICE
Guideline Development Group made a few import-
ant recommendations for essential future research,
including the urgent need to establish the
clinical-effectiveness and cost-effectiveness of using
different monitoring strategy in patients diagnosed
with glaucoma.3
The aim of glaucoma management is to reduce or
halt visual loss and preserve the patient’s quality of
life. Monitoring patients’ visual ﬁeld (VF) to detect
functional progression should be a key element of
that clinical management. Ideally, any VF progres-
sion should be ameliorated to a rate which is com-
patible with a sighted lifetime without signiﬁcant
disability. Rates of VF progression often vary widely
between patients and timely detection of progres-
sion requires accurate and consistent measurements
of VFs over a period of years.4 5 The European
Glaucoma Society (EGS) recommends that all
newly-diagnosed glaucoma patients should be tested
three times per year during the ﬁrst 2 years in order
to establish the rate of VF loss at an early stage.6
These ‘ideal’ monitoring intervals are supported by
results from studies using statistical modelling, com-
puter simulation or retrospective assessment of large
VF databases.7–9 In particular, Chauhan and collea-
gues published practical recommendations for meas-
uring rates of VF change in glaucoma patients based
on empirical data and statistical modelling; they
concluded that three examinations per year are
required to identify an overall change in mean devi-
ation (MD) of 4 dB over 2 years in a patient with
average VF variability.9
There is a strong rationale for frequent monitor-
ing to detect the rapidly progressing patient
because, from a healthcare planning perspective, the
cost of glaucoma management increases consider-
ably with the severity of visual loss.10 11 Meanwhile,
with a signiﬁcant number of patients having stable
treated disease, there are potential cost implications
by performing a greater number of tests than are
necessary. With the current incidence of COAG esti-
mated to be approximately 9000 new cases per year
(excluding glaucoma suspects or those with ocular
hypertension),3 valuable resources could be redis-
tributed by optimising the monitoring guidelines to
maintain disease stability; however, this could be
offset by reduced statistical sensitivity to detect VF
progression, which may in turn lead to disease wor-
sening and treatment escalation. This ﬁne balance is
further complicated by what is achievable with the
resources currently available.
The aim of this multi-centre cross-sectional study
was ﬁrst to ascertain the current practice of VF
testing for monitoring patients with glaucoma in
England and, second, to evaluate this practice in
relation to EGS and NICE guidelines. The results
are valuable for healthcare providers and represent
an important starting point for research on optimis-
ing VF testing in newly-diagnosed patients.
MATERIALS AND METHODS
Six hospitals in England were identiﬁed to ensure
good geographic coverage and even representation
from district secondary units and tertiary centres:
Calderdale and Huddersﬁeld NHS Trust,
Gloucestershire Hospitals NHS Trust, Norfolk and
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Norwich University Hospital NHS Trust, North Middlesex
University Hospital NHS Trust, Southport and Ormskirk NHS
Trust, and Portsmouth Hospitals NHS Trust. Consultant
ophthalmologists with a subspecialist interest in glaucoma from
each of these units were invited to participate in the study, and
all invitees agreed to take part.
All patients with COAG seen in specialist glaucoma clinics
during the last week of January 2012 were included in the study
with their case records reviewed retrospectively. Patients were
excluded from the study if they had undergone laser or ophthal-
mic surgery within 6 months prior to the day of their clinic visit.
Data including patient demographics, best corrected visual
acuity (BCVA), stage of disease, intraocular pressure (IOP), fre-
quency of VF testing (number and interval of tests) and planned
monitoring interval were recorded using a standardised pro
forma that was ﬁrst piloted in each hospital before the ﬁnal
amended version was used. Some units had used Snellen visual
acuity to record BCVA, while others had used logMAR charts.
For consistency, all Snellen BCVAs were converted into approxi-
mate logMAR equivalents to aid analysis.
The clinician’s opinion on IOP stability, the clinical interpret-
ation of VF, optic nerve head appearance and overall disease sta-
bility were also collected, with the possible responses collated in
table 1. Investigators were either specialist trainee doctors or
optometrists, and written instructions about the pro forma were
given to ensure the data collected were similarly detailed. To
avoid altered behaviour of assigning intervals during the study,
staff members at each hospital were unaware that the study was
being conducted.
Anonymised data were collated and analysed by the main
investigators (SF, CL). The Humphrey Field Analyser (Carl Zeiss
Meditec, California, USA) MD (mean deviation; dB) was used
as an estimate of a patient’s VF defect severity. MD is a standard
age corrected clinical measure of the overall severity of VF loss
with more negative values indicating greater VF loss. Patients
were also classiﬁed into different stages of disease based on the
Canadian Ophthalmological Society Glaucoma (COSG)
Guidelines,12 with early disease deﬁned as vertical cup to disc
ratio ≤0.65±mild VF defect; moderate disease as vertical cup to
disc ratio 0.7–≤0.85 or VF defect not involving 10° of ﬁxation;
and advanced disease as vertical cup to disc ratio >0.9 and/or
VF defect within 10° of ﬁxation. For ease of comparison, data
were analysed based on worse eye status for each patient, that is,
if the right eye (RE) of a patient had a higher IOP and more
advanced disease than their left eye (LE), the data of their RE
were used in analyses on the basis of IOP status. The monitoring
interval was deﬁned as the time assigned to the next VF examin-
ation (with or without optic nerve head examination); if a VF
test was not speciﬁcally booked, it was assumed that the next
recorded appointment would include a VF test.
Statistical analyses were carried out using R (Foundation for
Statistical Computing, Vienna, Austria). The non-parametric
Kruskal–Wallis test was used to compare data from different
groups, with statistical signiﬁcance deﬁned as p<0.05. This
study was reviewed by the Research and Ethics committee at
each hospital and is compliant with the Declaration of Helsinki.
We certify that all applicable institutional and governmental reg-
ulations concerning the ethical use of human volunteers were
followed during this research.
RESULTS
Demographics
A total of 104 patients were included in this study; 54% were
women. The median (IQR) age was 77 (70–84) years. The
median (IQR) time in attendance at the glaucoma clinic for
COAG was 5.5 (2.0–11.4) years, with 73 patients having at least
2 years of follow-up. The number of patients from each individ-
ual centre (after excluding glaucoma suspects, ocular hyperten-
sives, secondary glaucoma and those with recent intraocular
surgery) were as follows: 13 patients from Calderdale and
Huddersﬁeld NHS Trust; 20 from Gloucestershire Hospitals
NHS Trust; 19 from Norfolk and Norwich University Hospital
NHS Trust; 17 from North Middlesex University Hospital NHS
Trust; 31 from Southport and Ormskirk NHS Trust; and four
from Portsmouth Hospitals NHS Trust.
Data for RE and LE were comparable, including BCVA (mean
±SD: RE 0.23±0.34 logMAR; LE 0.18±0.25 logMAR), VF
MDs (RE −6.3±8.2 dB; LE −7.4±7.9 dB) and IOP (RE 15.4
±3.5 mm Hg; LE 15.5±4.1 mm Hg). The disease status (COSG
guidelines) was also comparable between eyes: in the RE and
LE, respectively, 28 and 32 cases were at early stages; 51 and 43
were at moderate stages; and 25 and 27 at advanced stages (two
patients had lost sight in the LE).
Worse eye characteristics are listed in table 2. One patient had
no follow-up details recorded and was excluded from further
analysis. Overall, 84.5% (87/103) of patients did not have
changes to their treatment after the study visit; 15.5% (16/103)
had medications adjusted; and 1.9% (2/103) were listed for
surgery.
Frequency of VF testing
The median (IQR) total number of VF tests per person since
diagnosis was 4 (2–7), which equates to 0.7 VF tests per year
over the average 7.2 years of follow-up. The median (IQR)
number of VFs in the ﬁrst 2 years since diagnosis was 2 (2–3),
ranging from 1 to 5 tests (ﬁgure 1A). The number of patients
diagnosed with COAG before publication of the NICE guide-
lines (pre-2009) was 69, while 35 patients were diagnosed in,
or after, 2009. Reviewing the VF history, among patients who
had at least six tests during their entire follow-up (n=39), the
median (IQR) duration to achieve this was 4.6 (3.7–6.0) years,
ranging from 2.2 to 17.5 years (ﬁgure 1B). No statistically sig-
niﬁcant relationship was found (using the Kruskal–Wallis test)
between the number of VFs performed and disease stage (early,
moderate, advanced), adequacy of the IOP control (adequate,
inadequate, not recorded), VF stability (stable, progressing,
unsure, not recorded), optic disc appearance (stable, progres-
sing, unsure, not recorded) or overall stability of the conditions
(stable, progressing, unsure, not recorded) (table 3).
Table 1 Parameters recorded regarding the intraocular pressure
(IOP) level and glaucoma progression status at the study visit
Question Possible responses
IOP on target? IOP on
target
– IOP high Not
recorded
VF defect
progression?
VF stable Unsure, further
observation
required
VF
progressing
Not
recorded
ONH appearance
progression?
ONH
stable
Unsure, further
observation
required
ONH
progressing
Not
recorded
Overall condition
progressing?
Overall
stable
Unsure, further
observation
required
Overall
progressing
Not
recorded
ONH, optic nerve head; VF, visual field.
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Monitoring intervals
Two patients were arranged to undergo surgery (one trabecu-
lectomy and one cataract surgery), and thus they were excluded
in this part of analysis. A total of 59 patient records contained
details for the time to the next VF examination while 43
records speciﬁed only the time interval to the next appointment.
The overall median (IQR) monitoring interval requested at the
study visit was 7.5 (3.8–8.0) months. In all, 84.5% of patients
had no changes made to their management. When patient out-
comes were considered according to NICE recommended moni-
toring intervals for complete examination (ie, including VF
testing and optic nerve head examination), 88/101 patients
(87.1%) were guidance compliant. Among the patients with
non-compliant outcomes, ﬁve of them had longer than recom-
mended interval for IOP monitoring, three had longer than
recommended VF monitoring interval while another three
patients had shorter VF monitoring intervals than NICE
recommendations.
No relationship was found between stability of VF defects
(Kruskal–Wallis test, p=0.25) and the monitoring interval
requested. The severity of disease also had no inﬂuence on the
monitoring interval requested (Kruskal–Wallis test, p=0.40).
The median (IQR) monitoring intervals requested for early,
moderate and advanced glaucoma were 7 (3–8), 8 (4–8) and 8
(4–8) months, respectively; while the median (IQR) intervals
requested were 8 (3–8) months for stable VF defects, 8 (4–8)
for progressing VF defects, 5 (3–6) for uncertain VF progression
and 8 (4–8) months for those with no comments on VF status
(ﬁgure 2A).
In contrast, monitoring intervals were signiﬁcantly shortened
when patients had inadequate IOP control or when the overall
clinical impression was disease progression (p<0.001 and
p<0.001, respectively). The median (IQR) monitoring intervals
were 8 (3–8) months for patients with adequate IOP control, 4
(2–5) for those with inadequate IOP control and 8 (7–8) for
patients with no comments on IOP control (ﬁgure 2B). For the
overall impression of disease status, the median IQR) monitor-
ing intervals were 8 (4–8) months for stable patients, 4 (2–5)
months for patients with disease progression, 6 (4–6) for those
with uncertain status and 6 (5–8) for those with no comments
on overall status.
DISCUSSION
This multi-centre cross-sectional study shows that no patients
received the frequency of VF testing recommended by Chauhan
et al9 and the EGS guidelines (six VFs in the ﬁrst 2 years).
Typically, patients had two to three VF tests in the ﬁrst 2 years
following diagnosis. The median time for six VF tests to be
undertaken was more than 4 years. Frequent VF tests after
initial diagnosis help to detect VF changes, and could determine
the speed of disease progression in each individual patient,
which subsequently allows the management to be appropriately
tailored.6 It is important to note that the speed (rate) of VF pro-
gression varies widely between patients and timely detection of
progression requires accurate and consistent measurement of
VFs over years. Notably, the frequency of VF testing suggested
by the EGS guidelines6 and Chauhan et al9 aims to determine,
with good certainty, rapidly changing eyes (MD <−2 dB/year).
Therefore, patients with slower progression will not be identi-
ﬁed as quickly (at the same statistical power).
For monitoring patients with glaucoma, the clinician’s aim is
to try and maintain patients’ visual function during their life-
time. Risk of visual impairment depends on the stage of disease
at presentation, the life expectancy as well as the rate of visual
deterioration.13 14 Clearly, patients with rapid VF progression
are at greater risk of suffering blindness than patients with slow
Table 2 Characteristics of patients with chronic open angle
glaucoma.
Worse eye characteristics
Mean logMAR visual acuity (±SD) 0.30 (±0.35)
Severity of glaucoma
Early 20
Moderate 50
Advanced 34
Mean IOP at study visit (±SD), mm Hg 16.3 (±3.9)
IOP status
Adequate 75
Inadequate 16
Not recorded 13
VF mean deviation at study visit, dB −7.17 (±8.55)
VF status
Stable 39
Progressing 12
Unsure 7
Not recorded 46
Optic nerve head status
Stable 60
Progressing 9
Unsure 3
Not recorded 32
Overall clinical impression
Stable 70
Progressing 17
Unsure 5
Not recorded 12
IOP, intraocular pressure; VF, visual field.
Figure 1 Visual ﬁeld (VF) testing. (A)
The number of VF tests performed for
the ﬁrst 2 years in patients with
minimum follow-up of 2 years; (B) The
time taken for patients to receive six
VF tests.
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progression; hence, one method to identify those patients who
require the most attention is to calculate their rates of VF loss
over time. Signiﬁcantly, recommendations of Chauhan et al9 do
not incorporate information about a patient’s level of VF
damage at presentation, which is an equally important consider-
ation when trying to ensure that a patient’s visual function
remains unaffected. Considering treatment and monitoring
costs, it is imperative that resources are prioritised in favour of
those patients who are in the greatest danger of suffering visual
disability in their lifetime.14
A signiﬁcant ﬁnding of the current study was the observation
that the value of VF test results for assigning future VF intervals
to clinicians seems limited. Our results suggest that overall clin-
ical impression is driven by the adequacy of IOP control rather
than VF test ﬁndings. IOP control is a modiﬁable risk factor for
disease progression and, therefore, it requires careful surveil-
lance. Nevertheless, perimetry is the only direct method for
monitoring functional change in patients. Therefore, it is sur-
prising that no relationship was found between stability of VF
defects, or the severity of disease, and the monitoring interval
requested. While recommended monitoring intervals were con-
sidered as NICE compliant, VF intervals were variable for a
given level of disease severity. The low frequency of VF testing
in newly-diagnosed patients observed in this study, at ﬁrst,
seems at odds with the statistic that 87% of decisions on moni-
toring intervals were compliant with NICE guidance. There is
insufﬁcient evidence to conclude which guidelines, EGS or
NICE, are likely to be most appropriate, but more research is
necessary to establish the clinical-effectiveness and cost-
effectiveness of the recommendations. Furthermore, unlike the
EGS guidelines, the exact NICE monitoring interval depends on
the disease severity and IOP relative to target IOP. So, for
patients with stable disease and adequate IOP, annual monitor-
ing is within NICE guidelines. Further, the intervals given by
NICE are fairly wide, so that the permitted interval spans 2–6
or 6–12 months. An earlier single-centre study by Tatham and
Murdoch also found that assigned intervals were in accordance
with NICE guidance.15
It is important to note that the current NICE guidelines have
been unable to identify any evidence with sufﬁcient quality
about the role of VF testing in glaucoma monitoring; this study
therefore provides important data on current UK practice of VF
monitoring. These data are useful for healthcare planning for
improving hospital resources. It is presumed that the current
rate of VF testing is consistent with the VF capacity of hospital
glaucoma outpatient services in terms of cost and staff restric-
tions. Increasing the number of VFs from the current practice to
meet EGS guidelines would require an approximately threefold
increase in the number of VFs for newly-diagnosed patients in
the ﬁrst 2 years, yet there is no evidence for whether the EGS
guidelines are feasible with the resources available. For example,
if resources are to be diverted, what is the detriment to other
patients whose VF test frequencies would become even less fre-
quent? This represents an important health service delivery
research and health-economic question given the large number
of patients being monitored. Some work on these issues is cur-
rently being undertaken.16 Furthermore, other studies have
investigated other types of VF follow-up schemes which may be
more efﬁcient.17 18
This retrospective study has its limitations. It is assumed that
the six units sampled are representative of national practice.
Being a cross-sectional study, sampling bias is an inherent issue.
Further, for each centre the patients sampled during the study
week are assumed to be representative of the general population
of COAG patients seen in that unit. The number of patients
from Portsmouth was only four, which is not comparable with
other participating centres. However, out of the 32 patients
seen in Portsmouth during the study week, 28 patients did not
meet the study inclusion criteria (17 had a diagnosis other than
COAG and 11 had recent intraocular surgery). Although the
Table 3 Median number of visual field (VF) tests by disease
severity and intraocular pressure (IOP)
Median no. of VF (IQR)
Severity of glaucoma
Early 3 (2–5)
Moderate 4 (1–7)
Advanced 6 (2–7)
IOP status
Adequate 4 (2–7)
Inadequate 2 (1–6)
Not recorded 5 (3–6)
VF status
Stable 5 (3–8)
Progressing 5 (2–7)
Unsure 4 (2–7)
Not recorded 2 (1–5)
Optic nerve head status
Stable 4 (2–7)
Progressing 3 (2–6)
Unsure 5 (3–7)
Not recorded 3 (1–6)
Overall clinical impression
Stable 4 (2–7)
Progressing 3 (1–6)
Unsure 7 (5–7)
Not recorded 4 (3–6)
Figure 2 Patient monitoring in
relation to clinical ﬁndings. (A) Box
plot of intraocular pressure (IOP) (with
or without optic nerve head
examination) monitoring intervals by
glaucoma progression status; (B)
Follow-up interval by IOP status.
(Horizontal lines represent medians.
Boxes represent 25% and 75%
quartiles. Each whisker extends 1.5
times the IQR; outliers are represented
by dots.) NR, not recorded.
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purpose of our study was not to draw comparisons between par-
ticipating hospitals, this unequal sampling across units could
bias our results. It is also worth noting that patients requiring
more intensive control are more likely to be included in the
study, and so there are likely to be a higher proportion of
patients with poor IOP control (and advanced glaucoma sever-
ity) than those with adequate IOP control in the study popula-
tion. However, this is likely to make the sample representative
of the distribution of patients (in terms of proportions with dif-
ferent IOP control and disease severity) seen in the clinic
annually.
Data were collected on patients since initial diagnosis and the
additional assumption has been made that clinical practice, in
terms of monitoring intervals, has remained unchanged during
this time. In addition, clinical note taking was often poor or
incomplete; several patient records contained no comments on
adequacy of IOP control, VF status or overall disease status.
Inevitably with any retrospective analysis of patient records it is
difﬁcult to draw certain conclusions since notes are often made
by multiple clinicians, with varying levels of expertise. Where
available, the clinician’s comments regarding optic disc and/or
VF progression were assumed to be documented and an accur-
ate representation of the patient’s clinical state in each case.
In conclusion, this study shows that the number of VF tests
performed in newly-diagnosed COAG patients in the ﬁrst
2 years of follow-up is much lower than the recommended
number suggested by current research and EGS guidelines. On
average, less than one VF test was performed per year over the
duration of follow-up in the patients captured by this cross-
sectional study. Monitoring intervals for the majority of
patients were in compliance with NICE glaucoma guidelines,
although the importance of VF testing on monitoring intervals
is limited. Further studies to determine the effect of VF testing
intervals on patient outcomes and cost-effectiveness are
required.
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